CAR T-Cell Therapy Outcomes Similar Across Accredited and Non-Accredited Centers, Study Finds
Event summary
- Florida Cancer Specialists & Research Institute (FCS) study found comparable quality and safety outcomes for CAR T-cell therapy in accredited and non-FACT-accredited centers.
- The study analyzed over 6,800 adult patients with diffuse large B-cell lymphoma receiving CAR T therapy.
- FCS will present the findings at the 2026 ASCO® Annual Meeting.
- FCS is expanding CAR T therapies across its clinics statewide to improve patient access.
The big picture
The study challenges the necessity of FACT accreditation for CAR T-cell therapy, suggesting that convenient access to care may be more critical for patient outcomes. This aligns with broader industry trends towards decentralizing advanced cancer treatments to improve accessibility. FCS's expansion initiatives could set a precedent for other oncology providers, potentially reshaping the landscape of CAR T-cell therapy delivery.
What we're watching
- Regulatory Impact
- Whether the findings will prompt a reevaluation of FACT accreditation requirements for CAR T-cell therapy centers.
- Market Expansion
- The pace at which FCS and other providers expand CAR T-cell therapy to non-accredited centers to improve patient access.
- Patient Outcomes
- How the shift towards non-accredited centers will affect long-term patient outcomes and resource use.
Related topics